Advertisement

Post-Surgical Systematic Active Immunotherapy: Rational and Experimental Basis

  • G. Mathé
  • L. Olsson
  • I. Florentin
  • N. Kiger
  • S. Orbach-Arbouys
  • J. I. Schulz
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 67)

Abstract

Those who accepted the preliminary results of postsurgical chemotherapy of minimal residual disease (MRD) with too much enthusiasm now feel deceived since the number of beneficial chemotherapy trials has not increased much and in addition the preliminary results in postmenopausal breast cancer are not any more significant [61] and in osteosarcoma they are markedly diminished [12,14,24]. This is a human but not a scientific deception for those who, realizing the mode of action of chemotherapy, have always stressed the fact that chemotherapy obeys first-order kinetics [65—67]: each cycle kills a number of logs of cells but this number re-increases during the intervals (Fig. la). Hence, the final loss depends on the number of logs of cells killed by each cycle, on the doubling time of the tumor, and on the interval (Fig. lb) that makes the possibility of killing all cells highly improbable. LE PECQ et al. [30], studying the correlation between the number of cells killed and the dose of the oncostatic, were able by increasing the dose of the agent to increase this number to 99.99% but not to 99.999% (Fig. 1 c).

Keywords

Acute Myeloid Leukemia Spleen Cell Suppressor Cell Specific Immunotherapy Cancer Immunol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alberts, D. S.: Adjuvant immunotherapy with BCG of advanced ovarian cancer: a preliminary report. In: Adjuvant therapy of cancer. Salmon, S. E., Jones, S. E. (eds.), pp. 327–334. Amsterdam, Oxford, New York: North Holland 1977Google Scholar
  2. 2.
    Amery, W.: Final results of a multicenter placebo controlled levamisole study of resectable lung cancer. In: Immune modulation and control of neoplasia by adjuvant therapy. Chirigos, M. A. (ed.). Cancer Treat. Rep. (1978) (in press)Google Scholar
  3. 3.
    Belpomme, D., Joseph, R., Lelarge, N.: Increase null cells in patients submitted to long-term active immunotherapy. Cancer Immunol. Immunother. 1, 113–114 (1976)CrossRefGoogle Scholar
  4. 4.
    Bekesi, J. G., Holland, J. F.: Active immunotherapy in leukaemia with neuraminidase modified leukemic cells. In: Tactics and strategy in cancer treatment. Mathé, G. (ed.), pp. 78–89. Heidelberg, New York: Springer 1977Google Scholar
  5. 5.
    Bruley Rosset, M., Florentin, I., Kiger, N., Mathé, G.: Comparative experimental immunophar- macology of three, nitrosoureas: RFCNU, RPCNU and chlororzotocin. (in preparation) (1978)Google Scholar
  6. 6.
    Bruley Rosset, M., Florentin, I., Kiger, N., Davigny, M., Mathé, G.: Comparisons of the effects of BCG and levamisole administration in young adult and aged mice. In: Immune modulation and control of neoplasia by adjuvant therapy. Chirigos, M. A. (ed.). Cancer Treat. Rep. (1978) (in press)Google Scholar
  7. 7.
    Cabanillas, F., Rodriguez, V., Bodey, G. P.: The impact of intensive chemotherapy on the duration of remission and survival of patients (PTS) with nodular malignant lymphomas (NML). Proc. Am. Soc. Clin. Oncol. 19, Abs. C-16 (1978)Google Scholar
  8. 8.
    Clarysse, A., Kenis, Y., Mathé, G.: Cancer chemotherapy. Its role in the treatment strategy of hematologic malignancies and solid tumors. Heidelberg, New York: Springer 1976Google Scholar
  9. 9.
    Economides, F., Bruley Rosset, M., Mathé, G.: Effect of pre-surgical active BCG immunotherapies on murine EA lymphosarcoma. Biomedicine 25, 372–375 (1976)PubMedGoogle Scholar
  10. 10.
    Economides, F., Bruley Rosset, M., Mathé, G.: Treatment of the B16 melanoma with tumorectomy combined or not with adenectomy, systemic or/and regional BCG immunotherapy. Med. Oncol. 5, S34 (1977)Google Scholar
  11. 11.
    EORTC Hemopathies Working Party, presented by P. Strychmans: A randomized trial comparing immunotherapy and chemotherapy as maintenance treatment of acute lymphoblastic leukemia. 2nd International Symposium on Therapy of Acute Leukemias. Rome, December 1977. (Abs. p. 129)Google Scholar
  12. 12.
    EORTC Osteosarcoma Working Party Group, presented by C. Jasmin: A randomized trial of adjuvant chemotherapy in osteogenic osteosarcoma: comparison of the alternance of sequential administrations of high doses adriamycin, methotrexate and cyclophosphamide with a 6 months administration of high dose adriamycin followed by a low dose semi continuous chemotherapy. In: RRCR Vol. 68, pp. 28–32. Berlin, Heidelberg, New York: Springer 1979Google Scholar
  13. 13.
    Fortner, J. G.: Management of recurrent malignant melanoma. 3rd International Symposium on Oncology. Teheran, March 1978 (Abs. 21)Google Scholar
  14. 14.
    Fossati-Bellani, F., Gasparini, M., Bonadonna, G.: Adriamycin in the adjuvant treatment of operable osteosarcoma. In: RRCR Vol. 68, pp. 25–27. Berlin, Heidelberg, New York: Springer 1979Google Scholar
  15. 15.
    Frei, E. (III.), Jaffe, N., Skipper, H. E., Gero, M. G.: Adjuvant chemotherapy of osteogenic sarcoma. Progress and perspectives. In: Adjuvant therapy of cancer. Salmon, S. E., Jones, S. J. (eds.), pp. 49–64. Amsterdam: Elsevier North Holland Biomedical Press 1977Google Scholar
  16. 16.
    Geffard, M., Orbach Arbouys, S.: Enhancement of T-suppressor activity in mice by high doses of BCG. Cancer Immunol. Immunother. 1, 41–43 (1976)CrossRefGoogle Scholar
  17. 17.
    Gonzalez, R., Spitler, L.: Effect of levamisole as a surgical adjuvant therapy on malignant melanoma. In: Immune modulation and control of neoplasia by adjuvant therapy. Chirigos, M. A. (ed.) Cancer Treat. Rep. (1978) (in press)Google Scholar
  18. 18.
    Gutterman, J. U., Rodrigues, V., Mavligit, G., Burgess, M. A., Gehan, E., Hersh, E. M., McCredie, K. B., Reed, R., Smith, T., Bodey, G. P. (Jr.), Preireich, E. J.: Chemo-immunotherapy of adult acute leukaemia prolongation of remission in myeloblasts leukemia with BCG. Lancet 2, 1405–1409 (1974)PubMedCrossRefGoogle Scholar
  19. 19.
    Hoerni, B., Chauvergne, J., Hoerni-Simon, G., Durand, M., Brunei, R., Lagarde, C.: BCG in the immunotherapy of Hodgkin’s disease andnon-Hodgkin’s lymphomas. Results of a controlled trial including 60 patients. Cancer Immunol. Immunother. 1, 109–112 (1976)CrossRefGoogle Scholar
  20. 20.
    Hudson, C. N., Levin, L., Mardy, J. E., Poulton, R. A., Curling, O. M., Crowther, M., English, P. E., Leighton, M.: Active specific immunotherapy for ovarian cancer. Lancet 2, 877–878 (1976)PubMedCrossRefGoogle Scholar
  21. 21.
    Ikonopisov, R. L.: The use of BCG in the combined treatment of malignant melanoma. Behring Inst. Mitt. 56, 206–214 (1975)Google Scholar
  22. 22.
    Imbach, J. L., Montero, J. L., Moruzzi, A., Serrou, B., Chenu, E., Hayat, M., Mathé, G.: The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals. Biomedicine 23, 410–413 (1975)PubMedGoogle Scholar
  23. 23.
    Jacquillat, C., Banzet, P., Civatte, J., Puissant, A., Cottenot, F., Israel, L., Berlaich, S., Chastaing, CL, Maral, J.: Adjuvant chemotherapy or immunotherapy in the management of primary melanoma of level III, IV or V (in this volume)Google Scholar
  24. 24.
    Jaffe, N.: 3rd Annual meeting of the medical oncology society. Nice. 4–6 December 1977Google Scholar
  25. 25.Kaufman, S. D., Carey, R. W., Cosimi, A. B., Wood, W. C.: Randomized trial of adjuvant therapy of “high risk” primary malignant melanoma. Proc. Am. Soc. Clin. Oncol. 19, 374 (1978) (Abs. C- 271)Google Scholar
  26. 26.
    Khalil, A., Bourut, C., Halle Pannenko, O., Mathé, G., Rappaport, H.: Histológica reactions or the thymus spleen, liver and lymph-nodes to intravenous and subcutaneous BCG injections. Biomedicine 22, 112–121 (1975)PubMedGoogle Scholar
  27. 27.
    Kiger, N., Bruley Rosset, M., Florentin, I., Schulz, J., Mathé, G.: Effect of acute versus chronic administration of BCG on immune responses in mice, (in preparation) (1978)Google Scholar
  28. 28.
    Kiger, N., Olsson, L., Florentin, I., Mathé, G.: Specific active immunotherapy of EA leukaemia (in preparation) (1978)Google Scholar
  29. 29.
    Lacour, F., Lacour, J., Spira, A.: Poly A-Poly U as an adjunct to surgery in the treatment of spontaneous murine mammary adenocarcinoma. In: Investigation and stimulation of immunity in cancer patients. Mathé, G., Weiner, R. (eds.), pp. 352–358. Heidelberg, New York: Springer 1974Google Scholar
  30. 30.
    Le Pecq, J. B., Dat-Xuong, N., Gosse, C., Paoletti, C.: A new antitumoral agent: 9 hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Proc. Natl. Acad. Sci. USA 71, 5078–5082 (1974)PubMedCrossRefGoogle Scholar
  31. 31.
    Martin, M., Bourut, C., Halle Pannenko, O., Mathé, G.: Routes other than i.v. injection to mice for BCG administration in active immunotherapy of L1210 leukemia. Biomedicine 23, 339–340 (1975)PubMedGoogle Scholar
  32. 32.
    Martyre, M. C., Weiner, R., Halle Pannenko, O.: The in vivo activity of soluble extract obtained from RC19 leukemia: the effect of the method of extraction. In: Investigation and stimulation of immunity in cancer patients. Mathé, G., Weiner, R. (eds.), pp. 405–407. Heidelberg, New York: Springer 1974Google Scholar
  33. 33.
    Mathé, G.: La dernière cellule. Presse Méd. 75, 2591–2593 (1967)PubMedGoogle Scholar
  34. 34.
    Mathé, G.: Immunothérapie active de la leucémie L1210 appliquée après la greffe tumorale. Rev. Fr. Etudes. Clin. Biol. 13, 881–883 (1968)Google Scholar
  35. 35.
    Mathé, G.: Prevention of chemotherapy complications: time toxicity, pharmacokinetic and logistic factors. In: Complications of cancer chemotherapy. Mathé, G., Oldman, R. K. (eds.). Berlin, Heidelberg, New York: Springer 1974Google Scholar
  36. 36.
    Mathé, G.: Side effects and possible harmful action of immunomanipulation. In: The prediction of chronic toxicity from short term studies, pp. 67–82. Amsterdam: Excerpta Medica 1975Google Scholar
  37. 37.
    Mathé, G.: Active immunotherapy of cancer. Immunoprophylaxis and immunorestoration. An introduction, 1st. ed. Berlin, Heidelberg, New York: Springer 1976Google Scholar
  38. 38.
    Mathé, G.: Is systemic active immunotherapy shifting from the middle age to a renaissance period? 1. The multiplication of randomized trials showing significant effect of active immunotherapy on residual minimal disease. Cancer Immunol. Immunother. (1978) (in press)Google Scholar
  39. 39.
    Mathé, G., Pouillart, P., Lapeyraque, F.: Active immunotherapy o 1210 leukaemia applied after the graft of tumour cells. Br. J. Cancer 23, 814–824 (1969)PubMedCrossRefGoogle Scholar
  40. 40.
    Mathé, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J. R., Hayat, M., De Vassal, F.: Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1969 1, 697–699PubMedCrossRefGoogle Scholar
  41. 41.
    Mathé, G., Hayat, M., Sakouhi, M., Choay, J.: L’action immuno-adjuvante du poly I:C chez la souris et son application au traitement de le L1210. C.R. Acad. Sci. (Paris) 272, 170–173 (1971)Google Scholar
  42. 42.
    Mathé, G., Halle Pannenko, O., Bourut, C.: BCG in cancer immunotherapy. II. Results obtained with various BCG preparations in a screenin study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy. Natl. Cancer Inst. Monogr. 39, 107–112 (1973)PubMedGoogle Scholar
  43. 43.
    Mathé, G., Halle Pannenko, O., Bourut, C.: Potentiation of a cyclophosphamide induced immunodepression by the administration of BCG. Transplant. Proc. 6, 431–433 (1974)PubMedGoogle Scholar
  44. 44.
    Mathé, G., Halle Pannenko, O., Bourut, C.: Immune manipulation by BCG administered before or after cyclophosphaniide for chemoimmunotherapy of L1210 leukaemia. Eur. J. Cancer 10, 661–665 (1974)PubMedGoogle Scholar
  45. 45.
    Mathé, G., Halle Pannenko, O., Bourut, C.: Interspersion of cyclophosphamide and BCG in the treatment of L1210 leukaemia and Lewis tumour. Eur. J. Cancer 13, 1095–1098 (1977)PubMedGoogle Scholar
  46. 46.
    Mathé, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J. R., Hayat, M., De Vassal, F.: Follow-up of the first (1962) pilot study on active immunotherapy of acute lymphoid leukaemia: a critical discussion. Biomedicine 24, 29–35 (1977)Google Scholar
  47. 47.
    Mathé, G., Halle Pannenko, O., Bourut, C.: Effectiveness of murine leukemia chemotherapy according to the immune state reconsideration of correlations between chemotherapy tumor cell killing and survival time. Cancer Immunol. Immunother. 2, 139–141 (1977)Google Scholar
  48. 48.
    Mathé, G., De Vassal, F., Schwarzenberg, L., Delgado, M., Weiner, R., Gil, M. A., Pena-Angulo, J., Belpomme, D., Pouillart, P., Machover, D., Misset, J. L., Pico, J. L., Jasmin, C., Hayat, M., Schneider, M., Cattan, A., Amiel, J. L., Musset, M., Rosenfeld, C., Ribaud, P.: Preliminary results of three protocols for the treatment of acute lymphoid leukaemia of children: distinction of two groups of patients according to predictable prognosis. Med. Pediatr. Oncol.4, 17–27 (1978)PubMedCrossRefGoogle Scholar
  49. 49.
    McKneally, M. F., Maver, C. H., Kausel, H. W.: Intrapleural BCG immunostimulation in lung cancer. Lancet 1, 1003 (1977)PubMedCrossRefGoogle Scholar
  50. 50.
    Olsson, L., Mathé, G.: A cytokinetic analysis of bacillus Calmette Guerin induced growth control of murine leukemia. Cancer Res. 37, 1743–1749 (1977)PubMedGoogle Scholar
  51. 51.
    Olsson, L., Ebbessen, P., Kiger, N., Florentin, I., Mathé, G.: The antileukemic effect of systemic non-specific BCG immunostimulation with irradiated isogenic leukemic cells. Eur. J. Cancer 14, 355–362 (1978)PubMedGoogle Scholar
  52. 52.
    Orbach Arbouys, S., Castes, M., Berardet, M.: Enhancement of immunological responses by methotrexate pretreatment as a result of an eventual elimination of suppressor cells. In: Experiental hematology today. Berlin, Heidelberg, New York: Baum Springer (in press) (1978)Google Scholar
  53. 53.
    Paterson, A. H. G., Watson, M., Williams, D., McPherson, T. A.: Bacille Calmette-Guerin (BCG) immunotherapy in stage I, Clark’s level (CL) 3–5 malignant melanoma. Proc. Am. Soc. Clin. Oncol. 19, 389 (1978) (Abst. C-332)Google Scholar
  54. 54.
    Pavlovsky, S., Garay, G., Giraud, C., Sackman, F., Hayes, A., Svarch, E.: Chemo-immunotherapy with levamisole (LMS) in acute lymphocytic leukemia (ALL). Proc. Am. Assoc. Cancer Res. 19, 204 (1978) (Abs. 814)Google Scholar
  55. 55.
    Polak, L., Turk, J. L.: Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 249, 654–656 (1974)PubMedCrossRefGoogle Scholar
  56. 56.
    Pouillart, P., Mathé, G., Palangie, T., Schwarzenberg, L., Huguenin, P., Morin, P., Gautier, M., Parrot, R.: Trial of BCG immunotherapy in the treatment of resectable squamous cell carcinoma on the bronchus (stage I and II). Cancer Immunol. Immunother. 1, 271–273 (1973)Google Scholar
  57. 57.
    Powles, R. L., Crowther, D., Beteman, C. J. T., Beard, M. E. J., Mac Elwain, T. J., Russel, J., Lister, T. A., Whitehouse, J. M. A., Wrigley, P. F. M., Pike, M., Alexancer, P., Hamilton Fairley, G.: Immunotherapy for acute myelogenous leukaemia. Br. J. Cancer 28, 365–376 (1973)PubMedCrossRefGoogle Scholar
  58. 58.
    Reizenstein, P., Brenning, G., Engstedt, L., Franzen, S., Gahrton, G., Gullbring, B., Holm, G., Hocker, P., Hoglund, S., Hornstein, P., Jamenson, S., Killander, A., Killander, D., Klein, E., Lantz, B., Lidemalm, C., Lockner, D., Lonnqvist, B., Mellstedt, H., Palmblad, J., Pauli, C., Skarberg, K. O., Uden, A. M., Vanky, F., Wadman, B.: Effect of immunotherapy on survival and remission duration in acute, non-lymphatic leukaemia. In: Immunotherapy of cancer: present status of trials in man. Terry, W. D., Windhorst, D. (eds.), pp. 329–339. New York: Raven Press 1978Google Scholar
  59. 59.
    Renoux, G., Renoux, M.: Levamisole inhibits and cures a solid malignant tumour and its pulmonary metastases in mice. Nature New Biol.240, 217–218 (1972)PubMedCrossRefGoogle Scholar
  60. 60.
    Rojas, A. F., Feierstein, J. N., Glait, H. M., Olivari, A. J.: Levamisole action in breast cancer stage III. In: Immunotherapy of cancer: present status of trial in man. Terry, W. D., Windhorst, D. (eds.), pp. 635–645. New York: Raven Press 1978Google Scholar
  61. 61.
    Rossi, A., Valagussa, P., Bonadonna, G.: Combined modality management of operable breast cancer (in this volume)Google Scholar
  62. 62.
    Salmon, S. E.: Kinetic rationale for adjuvant chemotherapy of cancer. In: Adjuvant therapy of cancer. Salmon, S. E., Jones, S. J. (eds.), pp. 15–27. Amsterdam, Elsevier North Holland Biomedical Press 1977Google Scholar
  63. 63.
    Schultz, R. M., Chirigos, M. A., Pavlidis, N., Stylos, W.: Cytotoxic activity of interferon treated macrophages studied by various inhibitors. In: Immune modulation and control of neoplasia by adjuvant therapy. Chirigos, M. A. (ed.). Cancer Treat. Rep. (1978) (in press)Google Scholar
  64. 64.
    Scott, M. T.: Depression of delayed-type hypersensitivity by Corynebacterium parvum: mandatory role of the spleen. Cell. Immunol. 13, 251–263 (1974)PubMedCrossRefGoogle Scholar
  65. 65.
    Skipper, H. E., Schabel, F. M., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother. Rep. 35, 1–111 (1964)PubMedGoogle Scholar
  66. 66.
    Skipper, H. E., Schabel, F. M., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother. Rep. 45, 5–28 (1966)Google Scholar
  67. 67.
    Skipper, H. E., Schabel, F. M., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XXI. Schedulling of arabinosylcytosine to take advantage of its S-phase specificity against leukaemic cells. Cancer Chemother. Rep. 51, 125–165 (1967)PubMedGoogle Scholar
  68. 68.
    Stewart, T. H. M., Hollinshead, A. C., Harris, J. E., Raman, S., Belanger, R., Crepeau, A., Crook, A. F., Hirte, W. E., Hooper, D., Klaassen, D, J., Rapp, E. F., Sachs, H. J.: Survival study of immunochemotherapy in lung cancer. In: Immunotherapy of cancer: present status of trial in man. Terry, W. D., Windhorst, D. (eds.), pp. 203–216. New York: Raven Press 1978Google Scholar
  69. 69.
    Taguchi, T.: Experimental and clinical studies on krestin. In: Immune modulation and control neoplasia of neoplasia by adjuvant therapy. Chirigos, M. A. (ed.). Cancer Treat. Rep. (1978) (in press)Google Scholar
  70. 70.Terry, W. D., Windhorst, D. (ed.): Immunotherapy of cancer: present status of trials in man. New York: Raven Press 1978Google Scholar
  71. 71.
    Udem, A. M., Lindemalm, C., Pauli, C., Vanky, F., Reizenstein, P.: Effects of immunotherapy and chemotherapy on immunocompetence. A study of patients with acute myeloblasts leukemia in remission. Cancer Immunol. Immunother. (1978) (in press)Google Scholar
  72. 72.
    Vogler, W. R., Chan, Y. K.: Prolonging remission in myeloblasts leukaemia by tice-strain bacillus Calmette-Guerin. Lancet 1974 II, 128–131CrossRefGoogle Scholar
  73. 73.
    Vogler, W. R., Bartolucci, A. A., Omura, G. A., Miller, D., Smalley, R., Knopse, W. H., Goldstein, A.: A randomized clinical trial of BCG in myeloblastic leukemia conducted by the Southeastern Cancer Study Group. In: Immunotherapy of cancer: present status of trials in man. Terry, W. D., Windhorst, D. (eds.), pp. 365–373. New York: Raven Press 1978Google Scholar
  74. 74.
    Wanebo, H. J., Hilal, E., Strong, E. W., Pinsky, C., Oettgen, H. F., Hirshaut, Y.: Randomized trial of levamisole in patients with squamous cell carcinoma of the head and neck. In: Immune modulation and control of neoplasia by adjuvant therapy. Chirigos, M. A. (ed.). Cancer Treat. Rep. (1978) (in press)Google Scholar
  75. 72.
    Whittaker, J. A., Slater, A. J.: The immunotherapy of acute myelogenous leukaemia using intravenous BCG. In: Immunotherapy of cancer: present status of trials in man. Terry, W. D., Windhorst, D. (eds), pp. 393–404. New York: Raven Press 1978Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • G. Mathé
  • L. Olsson
  • I. Florentin
  • N. Kiger
  • S. Orbach-Arbouys
  • J. I. Schulz

There are no affiliations available

Personalised recommendations